Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 1/20 | 0.42 |
| ▸ | KDM1A | O60341 | 2/20 | 0.36 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.35 |
| ▸ | CCR1 | P32246 | 2/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 3/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19368196 | 0.89 | ADRB2 (0.41) | ADRB2KDM1ACCR1HRH3SLC6A2 | |
| SCHEMBL25136637 | 0.83 | ADRB2 (0.47) | ADRB2KDM1AHRH3ATMCHRM1 | |
| SCHEMBL18016896 | 0.83 | ADRB2 (0.47) | ADRB2KDM1AHRH3ATMCHRM1 | |
| SCHEMBL21300513 | 0.83 | ESR2 (0.50) | CYP2D6 | |
| SCHEMBL8719601 | 0.82 | TRPA1 (0.41) | CYP2D6 | |
| SCHEMBL353495 | 0.77 | ESR2 (0.47) | KDM1AATMCYP2D6 | |
| SCHEMBL19381903 | 0.77 | KDM1A (0.39) | ADRB2KDM1AFFAR4HRH3CNR2 | |
| SCHEMBL13369369 | 0.74 | DPP4 (0.41) | ADRB2KDM1ACCR1 | |
| SCHEMBL20329827 | 0.73 | KDM1A (0.40) | KDM1A | |
| SCHEMBL779666 | 0.72 | ATM (0.46) | KDM1AATMSLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9884048-B2 | ERK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2018-02-06 | — | — | US | disclosed |
| US-20170266167-A1 | ERK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170266167-A1 | ERK INHIBITORS | MAPK1, MAPK3, MAPK6 | ADRB2 1808/4885KDM1A 2624/4885FFAR4 2136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.